These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

183 related articles for article (PubMed ID: 22158074)

  • 1. Serum HSP70: a novel biomarker for early detection of pancreatic cancer.
    Dutta SK; Girotra M; Singla M; Dutta A; Otis Stephen F; Nair PP; Merchant NB
    Pancreas; 2012 May; 41(4):530-4. PubMed ID: 22158074
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Growth differentiation factor (GDF-15) concentration combined with Ca125 levels in serum is superior to commonly used cancer biomarkers in differentiation of pancreatic mass.
    Hogendorf P; Durczyński A; Skulimowski A; Kumor A; Poznańska G; Strzelczyk J
    Cancer Biomark; 2018 Feb; 21(3):505-511. PubMed ID: 29171983
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Metabolic biomarker signature to differentiate pancreatic ductal adenocarcinoma from chronic pancreatitis.
    Mayerle J; Kalthoff H; Reszka R; Kamlage B; Peter E; Schniewind B; González Maldonado S; Pilarsky C; Heidecke CD; Schatz P; Distler M; Scheiber JA; Mahajan UM; Weiss FU; Grützmann R; Lerch MM
    Gut; 2018 Jan; 67(1):128-137. PubMed ID: 28108468
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Improved Pancreatic Adenocarcinoma Diagnosis in Jaundiced and Non-Jaundiced Pancreatic Adenocarcinoma Patients through the Combination of Routine Clinical Markers Associated to Pancreatic Adenocarcinoma Pathophysiology.
    Ferri MJ; Saez M; Figueras J; Fort E; Sabat M; López-Ben S; de Llorens R; Aleixandre RN; Peracaula R
    PLoS One; 2016; 11(1):e0147214. PubMed ID: 26808421
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Circulating Heat Shock Protein 70 Is a Novel Biomarker for Early Diagnosis of Lung Cancer.
    Tang T; Yang C; Brown HE; Huang J
    Dis Markers; 2018; 2018():6184162. PubMed ID: 30245753
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Trefoil factor(s) and CA19.9: A promising panel for early detection of pancreatic cancer.
    Jahan R; Ganguly K; Smith LM; Atri P; Carmicheal J; Sheinin Y; Rachagani S; Natarajan G; Brand RE; Macha MA; Grandgenett PM; Kaur S; Batra SK
    EBioMedicine; 2019 Apr; 42():375-385. PubMed ID: 30956167
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical value of serum neopterin, tissue polypeptide-specific antigen and CA19-9 levels in differential diagnosis between pancreatic cancer and chronic pancreatitis.
    Talar-Wojnarowska R; Gasiorowska A; Olakowski M; Lekstan A; Lampe P; Malecka-Panas E
    Pancreatology; 2010; 10(6):689-94. PubMed ID: 21242708
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Serum dickkopf-1 is a novel serological biomarker for the diagnosis and prognosis of pancreatic cancer.
    Han SX; Zhou X; Sui X; He CC; Cai MJ; Ma JL; Zhang YY; Zhou CY; Ma CX; Varela-Ramirez A; Zhu Q
    Oncotarget; 2015 Aug; 6(23):19907-17. PubMed ID: 26101916
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Distinct pathophysiological cytokine profiles for discrimination between autoimmune pancreatitis, chronic pancreatitis, and pancreatic ductal adenocarcinoma.
    Ghassem-Zadeh S; Gaida MM; Szanyi S; Acha-Orbea H; Frossard JL; Hinz U; Hackert T; Strobel O; Felix K
    J Transl Med; 2017 Jun; 15(1):126. PubMed ID: 28578701
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Inflammation, Tumoral Markers and Interleukin-17, -10, and -6 Profiles in Pancreatic Adenocarcinoma and Chronic Pancreatitis.
    Tanţău A; Leucuţa DC; Tanţău M; Boţan E; Zaharie R; Mândruţiu A; Tomuleasa IC
    Dig Dis Sci; 2021 Oct; 66(10):3427-3438. PubMed ID: 33184795
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Discriminating patients with early-stage pancreatic cancer or chronic pancreatitis using serum electrospray mass profiling.
    Hocker JR; Postier RG; Li M; Lerner MR; Lightfoot SA; Peyton MD; Deb SJ; Baker CM; Williams TL; Hanas RJ; Stowell DE; Lander TJ; Brackett DJ; Hanas JS
    Cancer Lett; 2015 Apr; 359(2):314-24. PubMed ID: 25637792
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evaluation of serum MUC5AC in combination with CA19-9 for the diagnosis of pancreatic cancer.
    Zhang J; Wang Y; Zhao T; Li Y; Tian L; Zhao J; Zhang J
    World J Surg Oncol; 2020 Feb; 18(1):31. PubMed ID: 32028958
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Serum tumor antigen REG4 as a diagnostic biomarker in pancreatic ductal adenocarcinoma.
    Takayama R; Nakagawa H; Sawaki A; Mizuno N; Kawai H; Tajika M; Yatabe Y; Matsuo K; Uehara R; Ono K; Nakamura Y; Yamao K
    J Gastroenterol; 2010; 45(1):52-9. PubMed ID: 19789838
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical significance of elevated serum soluble CD40 ligand levels as a diagnostic and prognostic tumor marker for pancreatic ductal adenocarcinoma.
    Chung HW; Lim JB
    J Transl Med; 2014 Apr; 12():102. PubMed ID: 24745825
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Differential diagnosis between chronic pancreatitis and pancreatic cancer: value of the detection of KRAS2 mutations in circulating DNA.
    Maire F; Micard S; Hammel P; Voitot H; Lévy P; Cugnenc PH; Ruszniewski P; Puig PL
    Br J Cancer; 2002 Aug; 87(5):551-4. PubMed ID: 12189555
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Adiponectin as a potential differential marker to distinguish pancreatic cancer and chronic pancreatitis.
    Chang MC; Chang YT; Su TC; Yang WS; Chen CL; Tien YW; Liang PC; Wei SC; Wong JM
    Pancreas; 2007 Jul; 35(1):16-21. PubMed ID: 17575540
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Diagnostic usefulness of serum interleukin 6 (IL-6) and C-reactive protein (CRP) in the differentiation between pancreatic cancer and chronic pancreatitis.
    Mroczko B; Groblewska M; Gryko M; Kedra B; Szmitkowski M
    J Clin Lab Anal; 2010; 24(4):256-61. PubMed ID: 20626020
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Usefulness of plasma vascular endothelial growth factor in the diagnosis of pancreatic carcinoma: differential diagnosis, tumor progression, and patient survival.
    Kobayashi A; Yamaguchi T; Ishihara T; Ohshima T; Baba T; Shirai Y; Tadenuma H; Nakamura K; Saisho H
    Pancreas; 2005 Jul; 31(1):74-8. PubMed ID: 15968251
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Panel of serum miRNAs as potential non-invasive biomarkers for pancreatic ductal adenocarcinoma.
    Khan IA; Rashid S; Singh N; Rashid S; Singh V; Gunjan D; Das P; Dash NR; Pandey RM; Chauhan SS; Gupta S; Saraya A
    Sci Rep; 2021 Feb; 11(1):2824. PubMed ID: 33531550
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Low serum miR-373 predicts poor prognosis in patients with pancreatic cancer.
    Hua Y; Chen H; Wang L; Wang F; Wang P; Ning Z; Li Y; Liu L; Chen Z; Meng Z
    Cancer Biomark; 2017 Jul; 20(1):95-100. PubMed ID: 28759959
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.